• Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using YEATS2 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using YEATS2 Polyclonal Antibody. Secondary antibody was diluted at 1:20000 cells nucleus extracted by Minute TM Cytoplasmic and Nuclear Fractionation kit (SC-003, Inventbiotech, MN, USA).

Anti-YEATS2 antibody (341-390 aa) (STJ96291)

SKU:
STJ96291

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-YEATS domain-containing protein 2 (341-390 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:5000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: YEATS2
Gene ID: 55689
Uniprot ID: YETS2_HUMAN
Immunogen Region: 341-390 aa
Specificity: YEATS2 Polyclonal Antibody detects endogenous levels of YEATS2 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human YEATS2 at the amino acid range 341-390
Protein Name Yeats Domain-Containing Protein 2
Database Links Reactome: R-HSA-3214847
Reactome: R-HSA-9772755
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Yeats Domain-Containing Protein 2 antibody
Anti-YEATS2 antibody
Anti-KIAA1197 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance